BYSI - BeyondSpring Inc.
| Previous Close | 26.31 |
| Open | 26.70 |
| Bid | 26.00 x 1000 |
| Ask | 27.80 x 800 |
| Day's Range | 26.55 - 27.09 |
| 52 Week Range | 19.55 - 48.49 |
| Volume | 6,393 |
| Avg. Volume | 12,654 |
| Market Cap | 623.17M |
| Beta | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -4.40 |
| Earnings Date | Jun 21, 2018 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 55.38 |
- GlobeNewswire•2 days ago
BeyondSpring to Host First-Quarter 2018 Financial Results Conference Call on June 21, 2018
NEW YORK, June 18, 2018-- BeyondSpring Inc., a global, clinical-stage biopharmaceutical company focused on the development of transformative cancer therapies, today announced that the Company will report ...
- GlobeNewswire•20 days ago
BeyondSpring to Present at Upcoming Conferences
BeyondSpring is a global, clinical-stage biopharmaceutical company developing innovative immuno-oncology cancer therapies with a robust pipeline from internal development and from collaboration with University of Washington in de novo drug discovery using ubiquitination platform. BeyondSpring’s lead asset, Plinabulin, is in a Phase 3 global clinical trial as a direct anticancer agent in the treatment of non-small cell lung cancer (NSCLC) and two Phase 2/3 clinical programs in the prevention of chemotherapy-induced neutropenia (CIN).
- GlobeNewswire•21 days ago
BeyondSpring Announces $20 Million Registered Direct Offering
BeyondSpring Inc. (BYSI) (“BeyondSpring”), a global, clinical-stage biopharmaceutical company focused on the development and commercialization of innovative cancer therapies, today announced that it has raised aggregate gross proceeds of $20 million through a registered direct offering of its ordinary shares to certain strategic investors (the “Investors”). On May 29, 2018, BeyondSpring entered into a series of securities purchase agreements (collectively, the “Purchase Agreements”) with the Investors pursuant to which the Company agreed to issue and sell, in a registered offering by the Company, an aggregate of 739,095 shares of the Company’s ordinary shares, par value $0.0001 per share (the “Shares”), at a purchase price of $27.06 per share, for aggregate gross proceeds of $20 million, before deducting offering expenses.
- GlobeNewswire•last month
BeyondSpring to Present Positive Data From Prospective Phase 2 Trial Comparing Plinabulin to Neulasta for the Prevention of Chemotherapy-Induced Neutropenia at 2018 ASCO Annual Meeting
BeyondSpring Inc. (BYSI), a global clinical-stage biopharmaceutical company focused on the development of transformative cancer therapies, today announced that the Company will present results of the Phase 2 portion of Study 105, a prospective Phase 2/3 trial of its lead asset, Plinabulin, during a poster presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting on June 4, 2018. Importantly, data from the study demonstrated that patients treated with Plinabulin dosed 30 minutes after docetaxel for the prevention of docetaxel chemotherapy-induced neutropenia (CIN) reported less bone pain, which was clinically meaningful, and had superior neutrophil counts and comparable neutropenia reduction compared to patients treated with Neulasta® (pegfilgrastim) 24 hours after docetaxel.
- Zacks•last month
BeyondSpring Inc. (BYSI) Sees Hammer Chart Pattern: Time to Buy?
BeyondSpring Inc. (BYSI) Sees Hammer Chart Pattern: Time to Buy?
- GlobeNewswire•last month
BeyondSpring to Present at the Deutsche Bank 43rd Annual Health Care Conference
NEW YORK, May 07, 2018-- BeyondSpring Inc., a global, clinical-stage biopharmaceutical company focused on the development of transformative cancer therapies, today announced that Lan Huang, Ph.D., Chairman, ...
- GlobeNewswire•2 months ago
BeyondSpring to Present Neutropenia Clinical Trial Data on Lead Asset, Plinabulin, at 2018 ASCO Annual Meeting
NEW YORK, April 25, 2018-- BeyondSpring Inc., a global clinical-stage biopharmaceutical company focused on the development of transformative cancer therapies, today announced that the Company will present ...
- TheStreet.com•2 months ago
BeyondSpring CEO Reveals Novel Tumor Therapy
New York-based BeyondSpring develops oncology products with Plinabulin, a small molecule that attacks tumors and can activate the Rho guanine nucleotide exchange factor GEF-H1, which could play a role in managing a variety of diseases. Research has confirmed "the roles of GEF-H1 in epithelial barrier permeability, cell motility and polarization, dendritic spine morphology, antigen presentation, leukemic cell differentiation, cell cycle regulation, and cancer," according to the National Health Institutes' NCBI. "GEF-H1 might also contribute to pathophysiological signaling involved in leukemias, and in cancers associated with mutated p53 tumor suppressor gene, epithelial and endothelial cell dysfunction, infectious disease, and cardiac hypertrophy.
- GlobeNewswire•2 months ago
BeyondSpring Presents Lead Asset’s Mechanism Data for Prevention of Chemotherapy-Induced Neutropenia
NEW YORK, April 17, 2018-- BeyondSpring Inc., a global, clinical-stage biopharmaceutical company focused on the development of transformative cancer therapies, today announced the presentation of preclinical ...
- Zacks•2 months ago
Why BeyondSpring (BYSI) Could Be a Potential Winner
Although overlooked by the investors, BeyondSpring (BYSI) looks well-positioned for a solid gain, supported by a favorable Zacks rank and positive estimate revisions.
- GlobeNewswire•3 months ago
BeyondSpring Files Its 2017 Annual Report on Form 20-F
NEW YORK, April 03, 2018-- BeyondSpring Inc., a global clinical stage biopharmaceutical company focusing on the development of innovative cancer therapies, today announced that the Company has filed its ...
- GlobeNewswire•3 months ago
BeyondSpring Provides Operational Update and Fourth-Quarter and Full-Year 2017 Financial Results
NEW YORK, April 03, 2018-- BeyondSpring Inc., a global, clinical-stage biopharmaceutical company focused on the development of transformative cancer therapies, today announced its fourth-quarter and full-year ...
- GlobeNewswire•3 months ago
BeyondSpring to Host Fourth-Quarter and Full-Year 2017 Financial Results Conference Call on April 3, 2018
NEW YORK, March 27, 2018-- BeyondSpring Inc., a global, clinical-stage biopharmaceutical company focused on the development of transformative cancer therapies, today announced that the Company will report ...
- GlobeNewswire•3 months ago
BeyondSpring Appoints Edward Dongheng Liu as Chief Financial Officer
NEW YORK, March 27, 2018-- BeyondSpring Inc., a global, clinical-stage biopharmaceutical company focused on the development of transformative cancer therapies, announced today the appointment of Edward ...
